Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 301–400 of 968
Hydrocortisone in Severe Community-Acquired Pneumonia
Dequin, P.-F., Meziani, F., & Gouge, A. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2307400 · Cited by 19
Haemodynamic management of septic shock
Kotani, Y., Ryan, N., Udy, A. A., & Fujii, T. (2024) · Burns & Trauma · doi:10.1093/burnst/tkae081 · Cited by 22
“Data on fludrocortisone were obtained from two trials [17, 120] and require further validation.”
Vasoplegia Syndrome After Cardiac Surgery
Castagna, F., Mehra, M. R., Nabzdyk, C. S., & Givertz, M. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.028 · Cited by 22
Wen, Y., Zhu, Y., Qimin, J., Guo, N., Cai, Y., & Shen, X. (2018) · Shock · doi:10.1097/shk.0000000000001202 · Cited by 18
“(27) Low risk Low risk Double Povoa et al.”
BackgroundProbiotics in septic acute kidney injury, a double blind, randomized control trial
Chavez-Iñiguez, J. S., Ibarra-Estrada, M. Á., Gallardo-González, A. M., Cisneros-Hernández, A., Granado, R. C., Chávez-Alonso, G., Hernández-Barajas, E. M., Romero-Muñoz, A. C., Avellaneda, F. R., Prieto-Magallanes, M. L., et al. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2260003 · Cited by 21
“For decades, different therapeutic agents have been investigated for the management of AKI associated with sepsis with disappointing results; the use of agents such as statins [55], erythropoietin [56], steroids [57], alkaline phosphatase [58] and pirfenidone [17] is an important justified effort, and the search for a…”
BackgroundVasoplegia in Heart, Lung, or Liver Transplantation: A Narrative Review
Ortoleva, J. P., Dalia, A. A., Convissar, D. L., Pisano, D. V., Bittner, E. A., & Berra, L. M. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.01.012 · Cited by 18
Why Understanding Sepsis Endotypes Is Important for Steroid Trials in Septic Shock
Antcliffe, D. B., & Gordon, A. C. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003833 · Cited by 18
Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock
Coleman, P. J., Nissen, A. P., Kim, D. E., Ainsworth, C., McCurdy, M. T., Mazzeffi, M. A., & Chow, J. H. (2019) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253219877876 · Cited by 18
“This trial was unable to detect any mortality benefit, but like APROCCHSS, it was able to detect faster resolution of shock and shorter duration of mechanical ventilation with the use of corticosteroids.(40,41) Patients with critical illness are also deficient in thiamine, and its administration within 24 hours of adm…”
MethodResultDiscovery of fusidic acid derivatives as novel STING inhibitors for treatment of sepsis
Long, J., Ying, T., Zhang, L., Yu, T., Wu, J., Liu, Y., Li, X., You, G., Zhang, L., & Bi, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114814 · Cited by 18
Wu, C.-H., Guo, L., Hao, D., Wang, Q., Ye, X., Ito, M., Huang, B., Mineo, C., Shaul, P. W., & Li, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1110516 · Cited by 26
“The APROCCHESS trial reported that the use of hydrocortisone plus fludrocortisone improved the 90-day survival in patients with septic shock (15).”
BackgroundGangopadhyay, K. K., Mukherjee, J. J., Sinha, B., & Ghosal, S. (2023) · Journal of Radiology and Clinical Imaging · doi:10.26502/jrci.2809076 · Cited by 18
Less is more: catecholamine-sparing strategies in septic shock
Venkatesh, B., Khanna, A. K., & Cohen, J. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05770-3 · Cited by 18
Vincent, J., Marini, J. J., & Pesenti, A. M. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5220-y · Cited by 18
Vitamin C and thiamine for sepsis: time to go back to fundamental principles
Fujii, T., Fowler, R., & Vincent, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06242-9 · Cited by 18
Liu, L., Wu, L., Chen, Y., Deng, R., Hu, Y., Tu, Y., & Fang, B. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1531275 · Cited by 24
Xu, Z., Zhang, J., Li, Z., Wu, H., Xu, H., Guo, Y., & Li, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107917 · Cited by 20
Tan, K., Simpson, A., Huang, S., Tang, B. M. P., McLean, A. S., & Nalos, M. (2019) · Critical Care Explorations · doi:10.1097/cce.0000000000000009 · Cited by 20
“Although advancements in treatment protocols have reduced in-hospital mortality (3, 4), therapies that improve sepsis survival by reducing organ dysfunction are scarce (5).”
Schlapbach, L. J., GIBBONS, K. S., Ridolfi, R., Harley, A., Cree, M., Long, D. A., Buckley, D. H. F., Erickson, S. J., Festa, M., George, S., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.663435 · Cited by 17
Zhang, X., Wang, X., Sun, L., Gao, G., & Li, Y. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00332-3 · Cited by 19
“This is consistent with the results of clinical studies that the use of hydrocortisone combined with fludrocortisone during the hyperinflammatory phase of sepsis reduces mortality in patients with sepsis at 90 days [2], and the use of thymidine α1 to enhance immunity during the immunosuppressive phase reduces mortalit…”
ResultLele, A. V., Vail, E. A., O’Reilly-Shah, V. N., DeGraw, X., Domino, K. B., Walters, A. M., Fong, C. T., Gomez, C., Naik, B. I., Mori, M., et al. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007001 · Cited by 17
“Despite the limitations, our study provides important insights into the frequency of hypotension and variability of anesthetic management practices in brain-dead organ donors during organ recovery procedures.”
Moskowitz, A. L., Yankama, T. T., Andersen, L. W., Huang, D. T., Donnino, M. W., & Grossestreuer, A. V. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034406 · Cited by 17
Cohen, J., Bellomo, R., Billot, L., Burrell, L. M., Evans, D. M., Finfer, S. R., Hammond, N. E., Li, Q., Liu, D. C., McArthur, C. J., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0281oc · Cited by 17
Cardiovascular Responses During Sepsis
Pecchiari, M., Pontikis, K., Alevrakis, E., Vasileiadis, I., Kompoti, M., & Koutsoukou, A. (2021) · Comprehensive physiology · doi:10.1002/cphy.c190044 · Cited by 19
Racic, T., Chang, A., Fernando, N., Brandli, A. A., Natoli, R., Penfold, P. L., Provis, J. M., & Rutar, M. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108765 · Cited by 17
New, Useful Criteria for Assessing the Evidence of Infection in Sepsis Research
Mellhammar, L., Elén, S., Ehrhard, S., Bouma, H. R., Ninck, L., Muntjewerff, E., Wünsch, D., Bloos, F., Malmström, E., & Linder, A. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000697 · Cited by 21
Kamps, N. N., Banks, R., Reeder, R., Berg, R. A., Newth, C. J. L., Pollack, M. M., Meert, K. L., Carcillo, J. A., Mourani, P. M., Sorenson, S., et al. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000003009 · Cited by 18
Meyer, E. J., Nenke, M. A., Rankin, W. A., Lewis, J. G., Konings, E. E. M., Slager, M. A., Jansen, T. C., Bakker, J., Hofland, J., Feelders, R. A., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13844 · Cited by 18
Berghe, T. V., & Hoste, E. A. J. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0196-2 · Cited by 20
“However, large clinical studies on exogenous steroid administration are showing conflicting results [29] , with some studies showing a mortality benefit [30, 31] , whereas other could not demonstrate a beneficial effect [32, 33] .”
ResultHydrocortisone in Vasodilatory Shock
Venkatesh, B., & Cohen, J. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.005 · Cited by 20
Boscolo, A., Spiezia, L., Campello, E., Bertini, D., Lucchetta, V., Piasentini, E., CASSAI, A. D., & Simioni, P. (2020) · Korean Journal of Anesthesiology · doi:10.4097/kja.19396 · Cited by 17
Vincent, J. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5401-8 · Cited by 17
“In patients with severe septic shock, I believe there is now good evidence that administration of moderate doses of hydrocortisone (200 mg/day in four doses) improves outcomes [10].”
BackgroundControversies in Sepsis Management—What is the Way Forward?
Lo, A. H., Kee, A. C. L., Li, A., & Rubulotta, F. M. (2020) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202090 · Cited by 16
Wayland, J., Teixeira, J. P., & Nielsen, N. D. (2024) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2024.06.010 · Cited by 23
Hydrocortisone and Risk Factors for Kidney Replacement Therapy in Septic Shock
Donaldson, L., Devaux, A., White, K. C., Rajbhandari, D., Cohen, J., Bellomo, R., Myburgh, J., Hammond, N. E., & Venkatesh, B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.12279 · Cited by 16
Travers, S. A. A., Bouvattier, C. M., Fagart, J., Martinerie, L., Viengchareun, S., Pussard, E., & Lombès, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00368.2019 · Cited by 17
Glucocorticoids with or without Fludrocortisone in Septic Shock
Venkatesh, B., Finfer, S. R., & Myburgh, J. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1804993 · Cited by 16
Immune Dysregulation in Sepsis. A Narrative Review for the Clinicians
Valsamaki, A., Vazgiourakis, V., Mantzarlis, K. D., Manoulakas, E., & Makris, D. A. (2025) · Biomedicines · doi:10.3390/biomedicines13102386 · Cited by 20
“Annane et al. (2018) [69] used a combination of hydrocortisone and fludrocortisone to significantly reduce the 90-day mortality rate in patients with septic shock.”
Effects of a single bolus of hydroxocobalamin on hemodynamics in vasodilatory shock
Ritter, L. A., Maldarelli, M. E., McCurdy, M. T., Yamane, D. P., Davison, D. L., Parrino, C. R., Yim, D. N., Lee, M., Mazzeffi, M. A., & Chow, J. H. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.09.024 · Cited by 15
Differential benefits of steroid therapies in adults following major burn injury
Al‐Tarrah, K., Tan, P., Acharjee, A., Hazeldine, J., Torlińska, B., Wilson, Y. T., Torliński, T., Moiemen, N. S., & Lord, J. M. (2022) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2022.04.007 · Cited by 15
Lin, W., Su, P., & Chen, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-49038-9 · Cited by 15
Girardis, M., Coloretti, I., Antonelli, M. M., Berlot, G., Busani, S., Cortegiani, A., PASCALE, G. D., Rosa, F. G. D., Rosa, S. D., Donadello, K., et al. (2024) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-024-00165-3 · Cited by 15
Gallic Acid Attenuates Sepsis‐Induced Liver Injury through C/EBPβ‐Dependent MAPK Signaling Pathway
Cai, Y., Zhao, D., Pan, Y., Chen, B., Cao, Y., Han, S., Lian, F., Zhang, Y., & Yan, X. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400123 · Cited by 15
The End of Corticosteroid in Sepsis: Fragile Results From Fragile Trials
Vargas, M., & Servillo, G. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003396 · Cited by 15
Effect of hydrocortisone on the 28-day mortality of patients with septic acute kidney injury
Pan, Y., Yang, C., Wu, X., Cai, Q., & Xin, W. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1658605 · Cited by 15
“(ADRENAL [7] and APROCCHSS [8]) reported in 2018”
BackgroundInfluentialMarino, L. O., & de Souza, H. P. (2020) · European Journal of Emergency Medicine · doi:10.1097/mej.0000000000000693 · Cited by 17
Systemic inflammatory response in cardiac surgery
Krichevskiy, L. А., Rybakov, V. Y., Dvoryadkin, A. A., & Николаевич, П. Д. (2021) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology202103194 · Cited by 15
Bitencourt, M. R., Batista, R. L., Biscotto, I. P., & Carvalho, L. R. S. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000493 · Cited by 16
“Several current studies present controversial results regarding the dosage of cortisol or free cortisol in this context, both at the basal time and after a stimulus (3,72-74).”
BackgroundCIRMI—a new term for a concept worthy of further exploration: a narrative review
Nethathe, G. D., Lipman, J., Anderson, R., & Feldman, C. H. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5572 · Cited by 15
“Corticosteroids may not be beneficial or may lead to a small reduction in mortality with a possible increase in the risk of hyperglycemia and neuromuscular weakness (12,77,128,130,131).”
BackgroundInfluentialThe controversial role of corticosteroids in septic shock
Pourmand, A., Whiteside, T., Yamane, D. P., Rashed, A. L., & Mazer-Amirshahi, M. E. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.04.045 · Cited by 16
“(2018) [4] Multicenter, double-blind, randomized Patients in severe septic shock, as defined by high Simplified Acute Physiology Score II, high lactate, and vasopressor dependency.”
BackgroundMethodInfluentialVenkatesh, B., & Cohen, J. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003834 · Cited by 15
Angiotensin II Brings More Questions Than Answers.
Farina, N., Bixby, A. L., & Alaniz, C. (2018) · Europe PMC (PubMed Central) · Cited by 15
Current Controversies in Sepsis Management
Moss, S. R., & Prescott, H. C. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1696981 · Cited by 15
Prognostic utility of procalcitonin and lactate clearance for in-hospital mortality in sepsis
Diab, R., Chebl, R. B., Barmo, N., Siblini, R., Makki, M. H., Tamim, H., & Dagher, G. A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1679297 · Cited by 14
Glucocorticoid-Induced Leucine Zipper: A Promising Marker for Monitoring and Treating Sepsis
He, Y., Xu, J., Sun, M., Fang, X., Peng, Z.-K., Pan, S., Zhou, T., Wang, Y., & Shang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.606649 · Cited by 16
“Recently, the APPROCHSS trial involving 1241 patients evaluated the effect of hydrocortisone plus fludrocortisone therapy and revealed a lower all-cause 90-day mortality and higher vasopressor-free days in the hydrocortisone plus fludrocortisone group than the placebo group (25).”
BackgroundInfection Risk of Lumbar Epidural Injection in the Operating Theatre Prior to Lumbar Fusion Surgery
Li, P., Hou, X., Gao, L., & Zheng, X. (2020) · Journal of Pain Research · doi:10.2147/jpr.s261922 · Cited by 14
Risk Factors and Management of Leukopenia After Kidney Transplantation: A Single-Center Experience
Henningsen, M., Jaenigen, B., Zschiedrich, S., Pisarski, P., Walz, G., & Schneider, J. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.04.011 · Cited by 14
Park, Y. J., Lee, M. J., Bae, J., Lee, J. H., Lee, H. A. R., Mun, S., Kim, Y.-S., Yune, C. J., Chung, T. N., & Kim, K. (2022) · Life · doi:10.3390/life12030421 · Cited by 15
“In the early 2000s, low doses of steroids were used in clinical trials, and some reported beneficial effects [1,7,8,12,19].”
BackgroundInfluentialNot all Shock States Are Created Equal
Khorsand, S., Helou, M. F., Satyapriya, V., Kopanczyk, R., & Khanna, A. K. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2022.11.002 · Cited by 17
The Eight Unanswered and Answered Questions about the Use of Vasopressors in Septic Shock
Hamzaoui, O., Goury, A., & Teboul, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144589 · Cited by 17
Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials
Wu, Q., Pennini, M. E., Bergmann, J. N., Kozak, M., Herring, K. D., Sciarretta, K. L., & Armstrong, K. L. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac381 · Cited by 15
Huang, P., Chen, Y., Zhang, H., Chen, B., Zhao, S., Feng, Y., Lei, S., & Wu, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850221 · Cited by 14
Sartini, C., Landoni, G., Belletti, A., Kotani, Y., Maimeri, N., Umbrello, M., Yavorovskiy, A. G., & Jabaudon, M. (2023) · Panminerva Medica · doi:10.23736/s0031-0808.23.04986-8 · Cited by 16
Corticosteroids in critically ill patients: A narrative review
Haan, B. J., Blackmon, S. N., Cobb, A., Cohen, H. E., DeVier, M., Perez, M. M., & Winslow, S. F. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2944 · Cited by 17
“86,87 The mechanism of action for corticosteroids in septic shock includes mitigation of relative adrenal insufficiency as well as sodium retention and reduction of capillary leakage.”
Risk of sepsis in patients with primary aldosteronism
TAIPAI Study Group, Chan, C., Hu, Y., Chen, L., Chang, C., Lin, Y.-F., Lai, T., Huang, K., Lin, Y., Wu, V., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2239-y · Cited by 13
“[31] revealed that the patients with septic shock who received hydrocortisone plus fludrocortisone for 7 days had better long-term outcome than the placebo group.”
BackgroundSmarter Use of Corticosteroids in Treating Patients with Septic Shock
Prescott, H. C., & Sussman, J. B. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29323 · Cited by 13
Bagate, F., Bedet, A., Tomberli, F., Boissier, F., Razazi, K., de Prost, N., Carteaux, G., & Dessap, A. M. (2021) · Annals of Intensive Care · doi:10.1186/s13613-021-00852-2 · Cited by 13
“Moreover, in recent randomized controlled trials assessing the benefit of corticosteroid therapy in septic shock, time to weaning from MV was shorter in the intervention group than the placebo group [26, 27].”
BackgroundBasic mechanisms in cardiogenic shock: part 2 – biomarkers and treatment options
Krychtiuk, K. A., Vrints, C. J., Wojta, J., Huber, K., & Speidl, W. S. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac022 · Cited by 13
Ilias, Ι., Vassiliou, A. G., Keskinidou, C., Vrettou, C. S., Orfanos, S. E., Kotanidou, Α., & Dimopoulou, I. (2023) · Biomedicines · doi:10.3390/biomedicines11071801 · Cited by 19
Marik, P. E. (2018) · Surgical Infections · doi:10.1089/sur.2018.111 · Cited by 14
Zhou, X., Hu, C., Yao, L., Fan, Z., Sun, L., Wang, Y., & Xu, Z. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.09.013 · Cited by 13
Abril, M. K., Khanna, A. K., Kroll, S., McNamara, C., Handisides, D. R., & Busse, L. W. (2018) · Journal of Critical Care · doi:10.1016/j.jcrc.2018.12.007 · Cited by 13
“in a separate analysis have shown a survival benefit with the use of low dose combination steroids [23].”
BackgroundSepsis in a Panorama: What the Cardiovascular Physician Should Know
Gotur, D. B. (2018) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-14-2-89 · Cited by 15
Late Vasopressor Administration in Patients in the ICU
Viglianti, E. M., Bagshaw, S. M., Bellomo, R., McPeake, J. M., Molling, D. J., Wang, X. Q., Seelye, S. M., & Iwashyna, T. J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.071 · Cited by 13
Forceville, X., Antwerpen, P. V., & Preiser, J. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8063 · Cited by 14
“Numerous phase III studies performed over the last few decades have failed to demonstrate improved outcomes of patients with sepsis with the interventions studied, most probably because of the great complexity of the pathophysiology of sepsis (14, 90, 208).”
Self-citationDesign, Synthesis, and Anti-Inflammatory Activities of 12-Dehydropyxinol Derivatives
Wang, Y., Mi, X., Du, Y., Li, S., Yu, L., Gao, M., Yang, X., Song, Z., Yu, H., & Yang, G. (2023) · Molecules · doi:10.3390/molecules28031307 · Cited by 13
“Glucocorticoids (GCs) are the most effective drugs that inhibit inflammation in clinical settings; however, their side effects are extremely serious [3].”
BackgroundNandish, H. K., Arun, C. S., Nair, H. R., Rajesh, G., Kumar, H., & Venu, R. P. (2019) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2019.405 · Cited by 13
Management of vasoplegic shock
Mistry, R. N., & Winearls, J. (2024) · BJA Education · doi:10.1016/j.bjae.2024.10.004 · Cited by 13
Eligibility Criteria of Randomized Clinical Trials in Critical Care Medicine
Heirali, A., Heybati, K., Sereeyotin, J., Khan, F. A., Yarnell, C. J., Krewulak, K. D., Murthy, S., Burns, K. E. A., Fowler, R., Fiest, K. M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54944 · Cited by 15
Wang, X., Wei, C., He, D., Huang, D., Zhao, Y., Ran, L., Wang, X., Yu, H., Liang, Z., & Gong, L. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11027-w · Cited by 15
Meersseman, P., Hernández‐Tejero, M., Diaz, J. M., Wauters, J., Hermans, G., Aziz, F., Ceunen, H., Prado, V., Langouche, L., Arteaga, M., et al. (2025) · Liver International · doi:10.1111/liv.70257 · Cited by 14
“Data from retrospective studies and RCTs on the effect of HCS supplementation for septic shock in both general and cirrhotic populations showed a beneficial haemodynamic impact with faster vasopressor reduction and more shock reversal, especially in patients with RAI [3–5, 11, 13, 22, 24, 25].”
Zhang, X., Huang, K., Wu, Z., Ding, R., Han, J., Zhang, Y., Lu, Y., Lu, Y., & Si, Y. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108971 · Cited by 14
Son, J.-Y., Shin, S., & Choi, Y. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060544 · Cited by 18
Yang, G., Mi, X., Wang, Y., Li, S., Yu, L., huang, X., Tan, S., & Yu, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106467 · Cited by 12
Corticosteroids for Septic Shock: Another Chapter in the Saga
Yerke, J. R., Strnad, K., & Bauer, S. R. (2019) · Hospital Pharmacy · doi:10.1177/0018578719829416 · Cited by 13
“trial in 2002 and the APROCCHSS trial included patients with multiple organ dysfunctions or patients who could not maintain target blood pressures despite fluid resuscitation and vasopressors.(13,16) The CORTICUS and ADRENAL trials included patients in shock, without specific requirements relating to fluid resuscitati…”
BackgroundMethodResultInfluentialBourcier, S., Hindlet, P., Guidet, B., & Dechartres, A. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000003746 · Cited by 14
Lin, L., Gu, H.-Y., Luo, J., Wang, L., Zhang, C., Niu, Y., & Zuo, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01101 · Cited by 14
The cost-effectiveness of adjunctive corticosteroids for patients with septic shock
Thompson, K., Taylor, C. B., Venkatesh, B., Cohen, J., Hammond, N. E., Jan, S., Li, Q., Myburgh, J., Rajbhandari, D., Saxena, M. K., et al. (2020) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00386-1 · Cited by 14
“38 Our results provide new information showing that use of corticosteroids in patients with septic shock is not associated with additional long term complications at 6 months.”
ResultGlucocorticoid resistance and hyperlactatemia: A tag team to worsen sepsis
Aziz, M., & Wang, P. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.08.007 · Cited by 12
50 Years of Sepsis Investigation/Enlightenment Among Adults—The Long and Winding Road
Dellinger, R. P., Levy, M. M., Schorr, C., & Townsend, S. R. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005203 · Cited by 12
Hydrocortisone in septic shock: all the questions answered?
Briegel, J., Huge, V., & Möhnle, P. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.120 · Cited by 12
“Recently, two large-scale RCT on hydrocortisone in patients with septic shock were published (13,14).”
BackgroundHellali, R., Dagdia, Z. C., Ktaish, A., Zeitouni, K., & Annane, D. (2024) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2024.108017 · Cited by 11
Self-citationSayce, A. C., Martínez, F. O., Tyrrell, B. E., Perera, N., Hill, M. L., Dwek, R. A., Miller, J. L., & Zitzmann, N. (2021) · Immunology · doi:10.1111/imm.13393 · Cited by 12
“with glucocorticosteroids) has demonstrated similar mixed efficacy in clinical trials [6, 7].”
BackgroundA Standardized Step-by-Step Approach for the Diagnosis and Treatment of Sepsis
Gao, Y., Wang, H., Zhang, Z. J., Pan, C. K., Wang, Y., Zhu, Y. C., Xie, F. J., Han, Q. Y., Zheng, J., Dai, Q. Q., et al. (2022) · Journal of Intensive Care Medicine · doi:10.1177/08850666221085181 · Cited by 13
Jackson, K. E., & Semler, M. W. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.05.003 · Cited by 11
The Metabolomics of Critical Illness
Pacheco-Navarro, A. E., & Rogers, A. J. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_622 · Cited by 13
Corticosteroids in sepsis and community-acquired pneumonia
Guzzardella, A., Motos, A., Vallverdú, J., & Torres, A. (2023) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-023-01093-w · Cited by 11
Philpotts, Y. F., Ma, X., Anderson, M. R., Hua, M. S., & Baldwin, M. R. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16138 · Cited by 12
“of participants, n (%) 152 869 (45) 78 577 (23) 109 523 (32)”
Wentowski, C. C., Inglés, D. P., & Nielsen, N. D. (2021) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2021.10.001 · Cited by 15
The Omics Complexity in Sepsis: The Limits of the Personalized Medicine Approach
Isac, S., Isac, T., Tănăsescu, M. D., Pavel, B., Andreescu, C. V., Badea, A.-G., Ojog, D., Teodorescu, G.-D., Laceanu, A., Trifan, C.-B., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14030225 · Cited by 12
“Both revealed that corticosteroids can shorten the duration of shock; however, the influence on survival differed between the two trials, with one of them reporting improved survival [68], while the other reported no difference [69].”
BackgroundResultA current appraisal of evidence for the approach to sepsis and septic shock
Varon, J., & Baron, R. M. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119856517 · Cited by 12
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.